Avid Bioservices Inc (CDMO)

$10.23

-0.09

(-0.87%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $10.13
    $10.76
    $10.23
    downward going graph

    0.98%

    Downside

    Day's Volatility :5.86%

    Upside

    4.93%

    downward going graph
  • $4.07
    $13.24
    $10.23
    downward going graph

    60.22%

    Downside

    52 Weeks Volatility :69.26%

    Upside

    22.73%

    downward going graph

Returns

PeriodAvid Bioservices IncSector (Health Care)Index (Russel 2000)
3 Months
40.41%
6.5%
0.0%
6 Months
52.44%
7.1%
0.0%
1 Year
-20.12%
9.8%
0.0%
3 Years
-58.87%
14.2%
-20.2%

Highlights

Market Capitalization
597.0M
Book Value
$0.96
Earnings Per Share (EPS)
-2.23
Wall Street Target Price
12.5
Profit Margin
-100.6%
Operating Margin TTM
-3.01%
Return On Assets TTM
-2.96%
Return On Equity TTM
-112.58%
Revenue TTM
139.9M
Revenue Per Share TTM
2.21
Quarterly Revenue Growth YOY
8.0%
Gross Profit TTM
31.5M
EBITDA
-7.6M
Diluted Eps TTM
-2.23
Quarterly Earnings Growth YOY
-0.8
EPS Estimate Current Year
-0.32
EPS Estimate Next Year
-0.19
EPS Estimate Current Quarter
-0.04
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Avid Bioservices Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 22.19%

Current $10.23
Target $12.50

Company Financials

FY19Y/Y Change
Revenue
53.6M
↓ 0.03%
Net Income
-4.2M
↓ 80.68%
Net Profit Margin
-7.86%
↑ 32.82%
FY20Y/Y Change
Revenue
59.7M
↑ 11.38%
Net Income
-7.3M
↑ 72.15%
Net Profit Margin
-12.15%
↓ 4.29%
FY21Y/Y Change
Revenue
95.9M
↑ 60.58%
Net Income
11.2M
↓ 254.52%
Net Profit Margin
11.7%
↑ 23.85%
FY22Y/Y Change
Revenue
119.6M
↑ 24.75%
Net Income
127.7M
↑ 1038.71%
Net Profit Margin
106.75%
↑ 95.05%
FY23Y/Y Change
Revenue
149.3M
↑ 24.81%
Net Income
560.0K
↓ 99.56%
Net Profit Margin
0.38%
↓ 106.37%
FY24Y/Y Change
Revenue
139.9M
↓ 6.27%
Net Income
-140.8M
↓ 25234.46%
Net Profit Margin
-100.6%
↓ 100.98%
Q1 FY23Q/Q Change
Revenue
38.0M
↑ 9.38%
Net Income
461.0K
↓ 139.88%
Net Profit Margin
1.21%
↑ 4.54%
Q2 FY23Q/Q Change
Revenue
39.8M
↑ 4.68%
Net Income
-309.0K
↓ 167.03%
Net Profit Margin
-0.78%
↓ 1.99%
Q3 FY23Q/Q Change
Revenue
37.7M
↓ 5.21%
Net Income
-2.1M
↑ 577.35%
Net Profit Margin
-5.55%
↓ 4.77%
Q4 FY23Q/Q Change
Revenue
25.4M
↓ 32.69%
Net Income
-9.5M
↑ 354.32%
Net Profit Margin
-37.44%
↓ 31.89%
Q1 FY24Q/Q Change
Revenue
33.8M
↑ 33.16%
Net Income
-6.0M
↓ 36.84%
Net Profit Margin
-17.76%
↑ 19.68%
Q2 FY24Q/Q Change
Revenue
43.0M
↑ 27.09%
Net Income
-123.1M
↑ 1949.68%
Net Profit Margin
-286.45%
↓ 268.69%
FY19Y/Y Change
Total Assets
78.4M
↓ 18.13%
Total Liabilities
25.3M
↓ 36.72%
FY20Y/Y Change
Total Assets
107.6M
↑ 37.28%
Total Liabilities
65.7M
↑ 159.5%
FY21Y/Y Change
Total Assets
265.5M
↑ 146.71%
Total Liabilities
187.8M
↑ 185.7%
FY22Y/Y Change
Total Assets
429.8M
↑ 61.89%
Total Liabilities
255.3M
↑ 35.97%
FY23Y/Y Change
Total Assets
451.1M
↑ 4.93%
Total Liabilities
261.6M
↑ 2.45%
FY24Y/Y Change
Total Assets
336.6M
↓ 25.38%
Total Liabilities
275.7M
↑ 5.38%
Q1 FY23Q/Q Change
Total Assets
450.4M
↑ 1.94%
Total Liabilities
265.0M
↑ 1.68%
Q2 FY23Q/Q Change
Total Assets
451.1M
↑ 0.14%
Total Liabilities
261.6M
↓ 1.3%
Q3 FY23Q/Q Change
Total Assets
442.3M
↓ 1.93%
Total Liabilities
251.7M
↓ 3.76%
Q4 FY23Q/Q Change
Total Assets
454.6M
↑ 2.78%
Total Liabilities
271.0M
↑ 7.64%
Q1 FY24Q/Q Change
Total Assets
455.2M
↑ 0.13%
Total Liabilities
275.1M
↑ 1.51%
Q2 FY24Q/Q Change
Total Assets
336.6M
↓ 26.07%
Total Liabilities
275.7M
↑ 0.22%
FY19Y/Y Change
Operating Cash Flow
-11.6M
↓ 56.68%
Investing Cash Flow
4.5M
↓ 24015.79%
Financing Cash Flow
-2.9M
↓ 112.87%
FY20Y/Y Change
Operating Cash Flow
5.8M
↓ 150.25%
Investing Cash Flow
-3.8M
↓ 183.89%
Financing Cash Flow
1.1M
↓ 138.28%
FY21Y/Y Change
Operating Cash Flow
31.2M
↑ 435.13%
Investing Cash Flow
-9.9M
↑ 158.76%
Financing Cash Flow
112.3M
↑ 10149.54%
FY22Y/Y Change
Operating Cash Flow
9.5M
↓ 69.65%
Investing Cash Flow
-56.4M
↑ 471.89%
Financing Cash Flow
3.2M
↓ 97.15%
FY23Y/Y Change
Operating Cash Flow
-12.9M
↓ 236.15%
Investing Cash Flow
-77.6M
↑ 37.63%
Financing Cash Flow
2.9M
↓ 9.26%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.9M
↑ 85.04%
Investing Cash Flow
-11.3M
↓ 67.17%
Financing Cash Flow
868.0K
↑ 117.0%
Q2 FY23Q/Q Change
Operating Cash Flow
2.8M
↓ 140.48%
Investing Cash Flow
-24.9M
↑ 119.59%
Financing Cash Flow
704.0K
↓ 18.89%
Q3 FY23Q/Q Change
Operating Cash Flow
-278.0K
↓ 109.93%
Investing Cash Flow
-14.1M
↓ 43.26%
Financing Cash Flow
748.0K
↑ 6.25%

Technicals Summary

Sell

Neutral

Buy

Avid Bioservices Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Avid Bioservices Inc
Avid Bioservices Inc
47.22%
52.44%
-20.12%
-58.87%
56.84%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Avid Bioservices Inc
Avid Bioservices Inc
1250.0
NA
NA
-0.32
-1.13
-0.03
NA
0.96
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Avid Bioservices Inc
Avid Bioservices Inc
Buy
$597.0M
56.84%
1250.0
-100.6%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Avid Bioservices Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 25.39M → 42.97M (in $), with an average increase of 23.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -6.00M → -123.10M (in $), with an average decrease of 1949.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 81.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 245.4%

Institutional Holdings

  • State Street Corporation

    9.20%

  • BlackRock Inc

    8.14%

  • Millennium Management LLC

    6.93%

  • Vanguard Group Inc

    5.76%

  • AltraVue Capital, LLC

    4.96%

  • 12 West Capital Management LP

    4.33%

Company Information

avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.

Organization
Avid Bioservices Inc
Employees
371
CEO
Mr. Nicholas Stewart Green B.Sc., MBA
Industry
Health Technology

Discover More

FAQs